Labcorp (LH) said Wednesday it launched a blood-based biomarker test called pTau-217/Beta Amyloid 42 Ratio to aid in the diagnosis of Alzheimer's disease.
The blood test confirm the presence of amyloid pathology, which is associated with the disease, the company said.
Labcorp said the test offers a sensitivity and specificity of 95%, which is "substantially equivalent" to the performance of amyloid positron emission tomography imaging and cerebrospinal fluid testing.
The test can be used in clinical trials in addition to clinical patient care, the company said.
Price: 236.59, Change: +3.94, Percent Change: +1.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.